title: Chemotherapy (CAP) for the treatment of advanced ovarian cancer and second-effort surgery in the second look.
abstract: Seventy-two patients with advanced ovarian cancer received CAP chemotherapy followed by laparotomy and 'second-effort' surgery. The overall response to CAP therapy was 80%. A complete pathological response (CPR) was obtained in 16 patients and partial microscopic (PMiR) and macroscopic responses in 7 and 33 cases, respectively. The actuarial survival for the entire group was 36% at 50 months with a median survival of 34 months. No significant differences in survival between the CPR and PMiR groups were found. Radical second-effort surgery showed a somewhat beneficial effect. The tumor size before chemotherapy (less than 5 cm) and FIGO stage III had a significantly favorable effect on response rate and survival.
authors.affiliation: Service of Oncology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain.
authors.forename: M B
authors.initials: MB
authors.lastname: Ojeda-González
authors.forename: I
authors.initials: I
authors.lastname: Alvárez-López
authors.forename: M C
authors.initials: MC
authors.lastname: Alonso-Muñoz
authors.forename: J
authors.initials: J
authors.lastname: Badía-Serra
authors.forename: E
authors.initials: E
authors.lastname: Delgado-Latre
authors.forename: L
authors.initials: L
authors.lastname: de Andrés-Basauri
authors.forename: J J
authors.initials: JJ
authors.lastname: López-López
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007813:Laparotomy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin